INNOVIVA, INC. Deferred Tax Liabilities, Gross
INNOVIVA, INC. (INVA) had Deferred Tax Liabilities, Gross of $31.79 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-02-25
- 2025-12-31: Deferred Tax Liabilities, Gross $31.79M.
- 2023-12-31: Deferred Tax Liabilities, Gross $563.00K.
- 2022-12-31: Deferred Tax Liabilities, Gross $5.77M.
| Period end | Deferred Tax Liabilities, Gross |
|---|---|
| 2025-12-31 | $31.79M 10-K · filed 2026-02-25 |
| 2023-12-31 | $563.00K 10-K · filed 2025-02-26 |
| 2022-12-31 | $5.77M 10-K/A · filed 2024-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |